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ABSTRACT: The 5-HT7 receptor (5-HT7R) is involved in a broad range of physiological conditions and
disorders. Currently, there is no validated clinical positron emission tomography (PET) tracer available;
however, we have recently developed a promising 11C-labeled candidate. In this project, we aimed to
further extend our eﬀorts and develop an 18F-labeled derivative, coined [18F]ENL30. Fluorine-18 has
several advantages over carbon-11 especially within the preclinical phase, where a long half-life usually
increases evaluation throughput. ENL30 was successfully synthesized in a low albeit suﬃcient overall yield.
Radiolabeling succeeded with a radiochemical yield of approximately 4.5%. Subsequent preclinical PET
studies revealed that [18F]ENL30 binds speciﬁcally to the 5-HT7R but suﬀered from aﬃnity to σ-receptors.
Additionally, we identiﬁed [18F]ENL30 to be a P-gp substrate in rats. However, we believe that
[18F]ENL30 may prove to be valuable in higher species that exhibit decreased P-gp dependency. If
required, σ-receptor binding could, in such studies, be selectively blocked potentially allowing for selective
5-HT7R imaging.
■ INTRODUCTION
The serotonergic system with its neurotransmitter serotonin (5-
hydroxytryptamine, 5-HT) is widely spread throughout the
brain and modulates a variety of psychological and behavioral
functions and disorders.1,2 In 1993, the 5-HT7 receptor (5-
HT7R) was identiﬁed and became themost recentmember to be
added to the serotonin receptor family.3−5 The 5-HT7R is a G-
protein-coupled receptor, positively coupled to adenylate
cyclase, with activation leading to the production of cyclic
adenosine monophosphate, which in turn is involved in a broad
spectrum of secondary cell activation pathways.2−5 The 5-HT7R
is abundant in the central nervous system (CNS) with the
highest concentrations in thalamus (tha), hypothalamus,
hippocampus, and cortex (see Table S1, Supporting Informa-
tion, for further details).6−10 Preclinical studies with, e.g., 5-
HT7R knockout mice, have associated this receptor with CNS
disorders such as depression, anxiety, and schizophrenia.1,11−16
Currently, there is no clinical imaging radiotracer available to
study the 5-HT7R in vivo.
1,17 Access to such a radiotracer would
enable the study of the receptor’s physiological function and its
involvement in various CNS diseases. Furthermore, since the 5-
HT7R displays the highest aﬃnity toward serotonin of all
serotonergic receptors, 5-HT7R neuroimaging could be a
valuable tool in determining changes in the concentration of
5-HT in the synaptic cleft.18 This could signiﬁcantly improve
our understanding of the involvement of endogenous 5-HT in
brain disorders19 and potentially provide a path for new
treatment options.
Positron emission tomography (PET) is a nuclear medicine
molecular imaging technique that can be used to visualize and
quantify receptor physiology in vivo.20−22 Consequently, a PET
tracer for the 5-HT7R would allow the study of this receptor
system in vivo and address the aforementioned research
questions. Several groups, including ours, have over the years
attempted to develop a 5-HT7R radiotracer, although so far with
limited success.9,23−29 For example, PET tracers evaluated in
pigs or cats with promising outcomes, such as [18F]2FP3 or
[11C]Cimbi-717 (Figure 1), did not produce a speciﬁc signal in
nonhuman primates.10,30 Other tracers failed at even earlier
evaluation stages.26,28,29
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Our group has recently developed an O-methylated carbon-
11-labeled derivative of the highly selective 5-HT7R antagonist
SB-269970 (Figure 1).31 This tracer ([11C]Cimbi-701) has
shown promising results in pigs,30 prompting us to extend this
work and develop an 18F-labeled analogue. Fluorine-18 has
several advantages over carbon-11 in respect to clinical
translation and also preclinical work in rodents. Namely, the
use of ﬂuorine-18 can result in higher spatial resolution.
Figure 1. Schematic overview of previously evaluated PET tracers for the 5-HT7R and the structure of the new potential PET tracer presented in this
work, [18F]ENL30.9,10,25,26,28,31
Scheme 1. Synthetic Overview of ENL30 (15)a
a(A) The synthesis of (R)-4-methyl-1-(2-(pyrrolidin-2-yl)ethyl)piperidine (10), (B) its sulfonyl chloride coupling partner (14) and the ﬁnal
coupling to form the sulfonamide product 15 (right). Reagents and conditions: (a) (Boc)2O, triethylamine (TEA), MeOH, Δ, 0.5 h; (b) p-TosCl,
Py, dichloromethane (DCM), 0 °Croom temperature (rt), overnight; (c) potassium cyanide (KCN), dimethyl sulfoxide (DMSO), 90 °C, 4 h;
(d) HCl (35%), AcOH, Δ, 6 h; (e) (Boc)2O, NaOH (2 M), acetone, 0 °Crt, 2.5 h; (f) borane−tetrahydrofuran (THF), THF, rt, ON; (g) (i)
MsCl, Py, DCM, 0 °Crt, 2 h; (ii) 4-methylpiperidine, acetonitrile (ACN), rt50 °C, ON; (h) triﬂuoroacetic acid (TFA)/DCM (1:1), rt, 0.5 h.
(i) BnBr, NaOH, MeOH, H2O, AcOH, ON; (j) 1-bromo-2-ﬂuoroethane, NaH, dimethylformamide (DMF), 0−60 °C, 20 h; (k) 1,3-dichloro-5,5-
dimethylhydantoin, ACN, AcOH, H2O, 0 °C, 5 h. (l) Et2O, NaOH, 0 °Crt, ON.
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Moreover, the longer half-life of ﬂuorine-18 (109 vs 20.4 min)
eases the use for multiple evaluation experiments with a single
production.21
■ RESULTS AND DISCUSSION
A common strategy to convert a carbon-11 tracer into a ﬂuorine-
18 analogue is to exchange a methoxy functional group for a
ﬂuoroethoxy moiety. [18F]MH.MZ is one of the many examples
where this strategy has been successfully applied.32−34 This
attractive approach is not thought to drastically impact the
pharmacological behavior of the tracer due to similar electronic,
inductive, and spatial properties of the twomoieties.34 In light of
that, we were inspired to apply this approach to [11C]Cimbi-701
and develop an 18F-labeled derivative ([18F]ENL30). The
reference compound ENL30 (15) was synthesized in a way
similar to a previously reported synthesis strategy that was
applied to a phenolic analogue (Scheme 1).31,35,36
A key intermediate for this synthesis route is (R)-4-methyl-1-
(2-(pyrrolidin-2-yl)ethyl)piperidine (10), which we initially
tried to synthesize with a procedure described by Lovell et al.31
However, the necessary intermediate tert-butyl-2-
(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (3)
and its subsequent transformation suﬀered from poor yields
(Tables 1 and 2). As such, other leaving groups and reaction
conditions were employed. The use of tosyl chloride and
pyridine in DCM resulted in suﬃcient yields of the tosylate (4),
which could then be satisfactorily transformed to the nitrile (5)
in DMSO. This led to an optimized and satisfying yield of
approximately 63% over those two steps (Tables 1 and 2).31,35,36
Several catalyst-mediated reaction routes have been reported
to form (10) directly from (5).31,37 However, in our hands, even
extensive optimization eﬀorts did not result in any satisfying
yields (see the Supporting Information for more details). It
appeared that although the initial hydrogenation did occur
(nitrile to imide) the catalyst failed to eliminate the ammonia in
the ﬁnal step. In light of that, a previously described multistep
route was chosen to synthesize (10) (Scheme 1). This strategy
was initially thought to be inferior since an unnecessary
deprotection/protection had to be applied. However, this
approach yielded in suﬃcient amounts of (10) that could be
used in a subsequent coupling step with another key
intermediate 3-(2-ﬂuoroethoxy)benzenesulfonyl chloride
(14).31,35,36,38 The synthesis of (14) is detailed in Scheme 1.
Notably, in the ﬁnal step in the synthesis of 14, the need for S-
deprotection was circumvented and allowed direct oxidation of
sulfur.39,40 In summary, the reference synthesis was completed
in 13 steps, ending up with an overall low yield of approximately
0.2%.
In the next step, radiolabeling of [18F]ENL30 ([18F]15) was
attempted applying a two-step labeling procedure starting from
the commercially available precursor SB-269970 (3-[[(2R)-2-
[2-(4-methyl-1-piperidinyl)ethyl]-1-pyrrolidinyl]sulfonyl]-phe-
nol, monohydrochloride) and the routinely produced synthon,
2-[18F]ﬂuoroethyl tosylate ([18F]FETos). Using this strategy,
[18F]15 could successfully be radiolabeled in a radiochemical
yield (RCY) ranging between 1.2 and 15% (decay corrected, n =
8), with satisfactory molar activities [108−197 GBq/μmol (n =
3)] and radiochemical purities of >98% (Scheme 2). The total
synthesis time including separation and formulation took less
than 180min. Amaximum amount of 0.9 GBqwas isolated using
this approach. Importantly, it was necessary to form the
phenolate before starting the labeling procedure. Adding the
base 40 min prior to initiating the reaction at 100 °C resulted in
the highest RCY.
Encouraged by these results, we performed autoradiographic
studies on coronal rat brain slices, containing thalamus, a high 5-
HT7R density region (Figure 2a−c).6−10 These studies were
conducted to determine the aﬃnity and selectivity of [18F]15
toward the 5-HT7R. A KD of 0.75 ± 0.5 nM (n = 9) for the 5-
HT7R could be determined in a saturation assay (Figure 2d).
Recently, a close analogues of [18F]15 displayed aﬃnity toward
σ-receptors when subjected to competition assays, so we
decided to evaluate the selectivity of [18F]15 toward these
receptors by performing autoradiographic blocking studies with
the 5-HT7R selective antagonist SB-269970 (Ki,5‑HT7 = 1.26 nM,
Ki,5‑HT5a = 32 nM, and Ki,σ−1 = 158 nM)
31,41 as well as with
haloperidol as a σ-receptor-blocking agent (Ki,D2 = 2 nM, Ki,D3 =
4 nM,Ki,σ−1 = 4 nM,Ki,α1 = 12 nM,Ki,σ−2 = 14 nM,Ki,D4 = 15 nM,
Ki,5‑HT2A = 70 nM, and Ki,5‑HT7 = 380 nM).
42−44 The results are
displayed in Figure 2e. We found a dose-dependent blocking
with both ligands, 13% blockage using a 50 nM solution of SB-
269970 and 10.5% blockage using a 50 nM solution of
Table 1. Incorporation of a Suitable Leaving Group
leaving
group
(LG) solvent base
temperature
(°C) time (h)
yield
(%)
OMs THF TEA −78rt 2 12.6
OTos DCM TEA, cat. DMAP rt 6 28.6
OTos DCM pyridine 0rt overnight 76.8
Table 2. Optimization of Nitrile Introduction
leaving group
(LG) solvent
temperature
(°C) time (h) XCN
yield
(%)
OMs DMF 100 6 NaCN 33.4
OMs EtOH reﬂux overnight KCN N/A
OTos DMSO 90 4 KCN 81.9
Scheme 2. Radiosynthesis of [18F]ENL30 ([18F]15) (a)
[18F]F−, K222, K2CO3, ACN, 80 °C, 3 min; (b) DMF, NaOH
(2N), 100 °C, 25 min
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haloperidol. Consequently, [18F]15, in addition to 5-HT7R
binding, also binds to σ-receptors.
Speciﬁc and selective PET imaging is dependent on three key
factors: (1) aﬃnity (1/KD), (2) regional target density (Bmax)
compared to the density of other oﬀ-targets, and (3) nonspeciﬁc
binding.19,22,45 In vivo nonspeciﬁc binding is usually only not
determinable in vitro, even though more lipophilic tracers tend
to have higher nonspeciﬁc binding.22,46 Target aﬃnity, oﬀ-target
binding, andBmax values can be determined in binding assays and
have to be evaluated in respect to Bmax over KD and their
according theoretical, observed binding ratios of the target to
another oﬀ-target (tBRtarget/off‑target).
45 Values more than 5 are
considered suitable in these calculations.45 For 15, these values
are of concern for the tBR5‑HT7R/σ‑receptors even in high 5-HT7R
density areas. This is because 15 displays a speciﬁc σ-receptor
binding component (Figure 2) and σ-receptors are 5-fold more
prevalent than the 5-HT7Rs in the highest binding region
(thalamus).6−9,47 Therefore, a speciﬁc σ-receptor block may be
needed to enable selective 5-HT7R imaging with [
18F]15.
Keeping that in mind, we started to evaluate [18F]15 in PET
experiments.
At ﬁrst, in vivo evaluation in rats was performed at baseline
conditions (Figure 3a,e,f); however, only low brain uptake was
observed. Syvan̈en et al. showed in 2009 that in rodents several
well-established PET tracers are P-glycoprotein (P-gp) eﬄux
transporter substrates. Although these tracers showed poor
brain uptake by the rat brain, they have suﬃcient brain uptake in
higher species.48 Motivated by this, we investigated whether
[18F]15 is also a P-gp transporter substrate to potentially explain
the low brain uptake. Inhibition of the P-gp eﬄux transporter
with elacridar49 led to increased brain uptake (Figure 3b,e,f),
and thus [18F]15 was conﬁrmed to be a P-gp eﬄux transporter
substrate in rats. Next, we tested whether the uptake of [18F]15
in the brain after P-gp inhibition represented speciﬁc binding to
the 5-HT7R. Brain distribution of [
18F]15 was imaged in rats
that were injected with elacridar and a speciﬁc 5-HT7R
antagonist: the highly 5-HT7R-selective SB-269970
31 or the
structurally diﬀerent antagonist Cimbi-717.9 Thalamus (tha)
and cerebellum (cb) were chosen as the brain regions of interest
due to the high abundance of 5-HT7R in thalamus and the low
abundance in cerebellum.6−9 We found that both compounds
reduced the area under the time-activity curves (TACs) (SB-
269970: tha = 21.6%, cb = 25.5%; Cimbi-717: tha = 38.5%, cb =
35.9%) (Figure 3c−g). The reduction in the thalamus was
expected since this is a high 5-HT7R density region. However,
the reduction in the cerebellum was to a certain degree
unexpected since it is a low 5-HT7R density region.
6−9 Oﬀ-target
binding of [18F]15 could explain this observation and since
[18F]15 displayed σ-receptor aﬃnity, we investigated whether σ-
receptor binding contributed to the observed PET signal. For
this purpose, we imaged [18F]15 distribution in rat brain under
P-gp inhibition with elacridar and sigma receptor blockade with
either the subtype-unselective σ-receptor antagonist haloperidol
(1 mg/kg) or the σ − 1 selective antagonist SA4503 (1.5 mg/
kg).50 We saw a reduction in the area under the time-activity
curves in thalamus and cerebellum both with haloperidol
(Figure 3f,g, tha = 24.1% and cb = 16.2%) and with SA4503
(Figure 3g, tha = 13.5% and cb = 12.7%). Accordingly, we
conclude that in rats the observed PET signal stems from both 5-
HT7R and σ-receptor aﬃnities. This could explain the larger
reduction in the PET signal seen in thalamus after pretreatment
with Cimbi-717 compared to SB-269970 since Cimbi-717 also
displays high aﬃnity for the σ-receptors. A biodistribution study
was conducted, concluding that the major excretion pathway
was through the kidneys in both situations and with the major
diﬀerence of distribution seen in brain uptake (Table 3). Full
time-activity curves can be found in the Supporting Information
(Figure S2).
Figure 2. Results of the in vitro evaluation of [18F]15. (a−d) Determination of KD and Bmax values of [18F]15 in the thalamus (Tha). (a) Coronal rat
brain slice displaying the total binding of [18F]15. (b) Coronal rat brain slice displaying the nonspeciﬁc binding of [18F]15 by blocking with SB-269970
(10 μm). (c) Location of brain slices, around bregma−1.8. (d)KD and Bmax were elucidated from one-sited (speciﬁc binding, SB) nonlinear regression
plotting the speciﬁc binding (SB) in nMof [18F]15 tracer concentration in nM. The data is based on ﬁve concentrations (0.1, 0.3, 0.7, 1, and 2 nM) and
experiments were repeated three times (n = 9). (e) In vitro autoradiography blocking study. The results are shown as a grouped barplot with the %
signal in thalamus compared to 0 nM (total binding) using diﬀerent concentrations (1, 10, 50, and 100 nM) of SB-269970 and haloperidol (n = 3).
Error bars represent standard deviation (SD).
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■ CONCLUSIONS
[18F]ENL30 ([18F]15) was successfully synthesized using a
convergent synthesis method. In rat brain slices in vitro, [18F]15
showed low nanomolar aﬃnity toward 5-HT7R (KD = 0.75 nM).
In vivo [18F]15 displayed speciﬁc binding to 5-HT7R but also to
σ-receptors. To which extent this will translate into higher
species will need to be determined, but it is likely that the P-gp
dependency of [18F]15 will present less of a problem.48 Even if
the in vivo PET signal of [18F]15 also turns out to represent
speciﬁc binding to σ-receptors in higher species, speciﬁc
blocking of σ-receptors could potentially enable PET imaging
of the 5-HT7R system.
■ EXPERIMENTAL SECTION
General Information. Solvents and reagents were pur-
chased from Sigma-Aldrich (Merck, Darmstadt, Germany) or
Thermo Fisher Scientiﬁc and used as received unless otherwise
noted. The precursors for the radiosynthesis, ethylene di(p-
toluenesulfonate) (Merck, Darmstadt, Germany) and SB-
269970 (Tocris Bioscience, Abingdon, U.K.), were commer-
cially available.
Figure 3.Results from the in vivo evaluation of [18F]15 in rats. Horizontal PET images of [18F]15 evaluated in rats (a−d); all summed images are from
5 to 120 min of a dynamic scan obtained in a high-resolution research tomography (HRRT) scanner. (a) Summed PET image of [18F]15 at baseline.
(b) Summed PET image of [18F]15 after pretreatment with elacridar (5 mg/kg). (c) Summed PET image of [18F]15 after pretreatment with elacridar
(5 mg/kg) and SB-269970 (3 mg/kg). (d) Summed PET image of [18F]15 after pretreatment with elacridar (5 mg/kg) and Cimbi-717 (3 mg/kg).
Time-activity curves (TACs) from PET evaluation of [18F]15 in rats (e, f). (e) Thalamus (Tha) TACs [18F]15 in the baseline condition, after
pretreatment with elacridar (5 mg/kg). (f) Thalamus (Tha) TACs of [18F]15 after pretreatment with elacridar (5 mg/kg), both elacridar (5 mg/kg)
and SB-269970 (3mg/kg) and elacridar (5mg/kg) and haloperidol (1 mg/kg). (g) Calculated area under the curve (AUC) for all TACs displayed as a
grouped barplot also indicating percentage AUC reduction above the blocking agent bars. All TACs are normalized to injected radioactivity and animal
weight to generate the standard uptake value (SUV). Used dose for SA4503 experiments was 1.5 mg/kg.
Table 3. Biodistribution of [18F]ENL30 in Female Long-Evans Rats (% ID/mL)a
organ 5 min 20 min 40 min 60 min 120 min
liver 0.72 ± 0.15 0.43 ± 0.07 0.39 ± 0.05 0.36 ± 0.04 0.39 ± 0.03
kidneys 1.76 ± 0.17 1.24 ± 0.15 1.04 ± 0.15 0.96 ± 0.15 0.82 ± 0.15
bladder 0.49 ± 0.14 1.43 ± 0.48 1.89 ± 0.06 1.81 ± 0.22 2.00 ± 0.45
brain (baseline) 0.21 ± 0.02 0.21 ± 0.02 0.22 ± 0.02 0.23 ± 0.02 0.26 ± 0.02
brain (elacridar) 0.90 ± 0.31 0.78 ± 0.29 0.68 ± 0.25 0.62 ± 0.21 0.56 ± 0.16
aData are presented as the mean ± standard deviation of four animals at 5, 20, 40, 60, and 120 min after intravenous injection of [18F]ENL30.
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NMR (1H, 13C) spectra were recorded on a 600 MHz Bruker
Avance III HD or a 400 MHz Bruker Avance II at room
temperature. Chemical shift (δ) is expressed in parts per million
and referenced to the residual solvent peak. The resonance
multiplicity is abbreviated as follows or combinations thereof: s
(singlet), d (doublet), t (triplet), p (quintet), and m (multiplet).
The analysis of the NMR spectra was performed using the
software MestReNova v12.0.0 (Mestrelab Research S.L.). Thin-
layer chromatography (TLC) was run on silica-plated aluminum
sheets (Silica gel 60 F254) from Merck. The spots were
visualized by ultraviolet light at 254 nm, and the fraction of
radioactivity on the TLC plates was measured with an instant
imager from Packard. Flash column chromatography was carried
out manually on silica gel 60 (0.040−0.063 mm). Analytical
high-performance liquid chromatography (HPLC) was per-
formed on a Dionex system consisting of a P680A pump, a UVD
170U detector, and a Scansys radiodetector. The HPLC system
was controlled by Chromeleon 6.8 software.
Synthesis of ENL30 (15). The reference compound ENL30
((R)-1-(2-(1-((3-(2-ﬂuoroethoxy)phenyl)sulfonyl)pyrrolidin-
2-yl)ethyl)-4-methylpiperidine) (15) was synthesized by a
multistep reaction with the ﬁnal step being the deprotection of
tert-butyl-(R)-2-(2-(4-methylpiperidin-1-yl)ethyl)pyrrolidine-
1-carboxylate (8) to (R)-4-methyl-1-(2-(pyrrolidin-2-yl)ethyl)-
piperidine (9) and subsequent coupling with its sulfonyl
chloride coupling partner 3-(2-ﬂuoroethoxy)benzenesulfonyl
chloride (13). (8) was synthesized by optimization of previous
protocols;31,35,36 see the Supporting Information. The synthesis
of (13) and the ﬁnal reaction step are described below.
3-(Benzylthio)phenol (12). Benzyl bromide (0.52 mL, 4.4
mmol) was added to a solution of 3-mercaptophenol (0.4 mL,
3.96 mmol) and sodium hydroxide (175.9 mg, 4.4 mmol) in
methanol (10 mL). The mixture was stirred overnight at room
temperature and was then diluted with water (20 mL) and acetic
acid (10 mL). The resultant mixture was then concentrated to
remove organic solvents. Also, the resultant precipitate was
collected by ﬁltration and washed with water to yield the pure
product (558.1 mg, 58.6%). 1H NMR (400 MHz, methanol-d4)
δ 7.35−7.20 (m, 5H), 7.09 (t, J = 7.7 Hz, 1H), 6.82−6.77 (m,
2H), 6.63 (ddd, J = 8.1, 2.3, 1.0 Hz, 1H), 4.14 (s, 2H). Figure
S21. Rf = 0.78 (7:3 Hept/EtOAc).
Benzyl(3-(2-ﬂuoroethoxy)phenyl)sulfane (13). To a sol-
ution of sodium hydride (61.89 mg, 2.58 mmol) in anhydrous
DMF (10 mL) under a nitrogen atmosphere was added a
solution of 12 (558.1 mg, 2.58 mmol) in anhydrous DMF (7
mL) under cooling at 0 °C. The solution was allowed to stir for
30 min, after which, with the solution still at 0 °C, 1-bromo-2-
ﬂuoroethane (0.2 mL, 2.58 mmol) was slowly added. The
mixture was stirred for a further 20 h at 60 °C. Then, the solvent
was removed in vacuo. The residue was then redissolved in ethyl
acetate, washed with water and brine, dried over MgSO4, and
concentrated. The crude product was then puriﬁed by ﬂash
chromatography (125.4 mg, 18.6%). 1H NMR (400 MHz,
methanol-d4) δ 7.36−7.22 (m, 5H), 7.19 (t, J = 8.0 Hz, 1H),
6.94 (ddd, J = 7.8, 1.8, 0.9 Hz, 1H), 6.89 (dd, J = 2.5, 1.7 Hz,
1H), 6.79 (ddd, J = 8.3, 2.5, 0.9 Hz, 1H), 4.78−4.73 (m, 1H),
4.66−4.61 (m, 1H), 4.20−4.17 (m, 1H), 4.16 (s, 2H), 4.13−
4.10 (m, 1H). Figure S22. Rf = 0.51 (7:3 Hept/EtOAc).
3-(2-Fluoroethoxy)benzenesulfonyl Chloride (14). To an
ice-cold solution of 13 (125.4 mg, 0.36 mmol) in a mixture of
acetonitrile (3.6 mL), water (0.1 mL), and acetic acid (0.15
mL), 2,4-dichloro-5,5-dimethylhydontoin (141.8 mg, 0.72
mmol) was added portion wise. The reaction mixture was
stirred at 0 °C while monitoring the consumption of starting
material by TLC. Upon consumption of the starting material,
the solution was concentrated to near dryness in vacuo. The
crude product was then diluted with DCM (4.5 mL), and the
solution was cooled once more to 0 °C. The solution was then
diluted further with an aqueous 5% NaHCO3 solution. The
mixture was stirred for a further 15 min. The lower organic layer
was then washed with an aqueous 10% brine solution, and the
resultant organic layer was dried over MgSO4 and concentrated
in vacuo to give an acceptably pure product (85.9 mg, 100%). 1H
NMR (600 MHz, chloroform-d) δ 7.68−7.65 (m, 1H), 7.55−
7.52 (m, 2H), 7.31 (dt, J = 8.3, 1.6 Hz, 1H), 4.85−4.82 (m, 1H),
4.77−4.74 (m, 1H), 4.35−4.31 (m, 1H), 4.31−4.27 (m, 1H).
13C NMR (151 MHz, chloroform-d) δ 158.87, 145.23, 130.75,
122.41, 119.68, 111.85, 81.91, 80.77. Figures S23 and S24. Rf =
0.43 (7:3 Hept/EtOAc).
(R)-1-(2-(1-((3-(2-Fluoroethoxy)phenyl)sulfonyl)pyrrolidin-
2-yl)ethyl)-4-methylpiperidine (ENL30) (15). 9 (4.5 mg, 15.2
μmol) was dissolved in a 1:2 solution of TFA and DCM (1.5
mL), and the resulting solution was stirred under nitrogen for 30
min. The organics were then removed in vacuo, and the residual
salt was dissolved in 5 mL of 2MNaOH at 0 °C. To the aqueous
solution was added 14 (13.7 mg, 41.9 μmol) in diethyl ether (4
mL) while still at 0 °C. The resultant biphasic solution was
stirred vigorously overnight while warming to room temper-
ature. The reaction mixture was diluted with DCM and acidiﬁed
to pH 5. The organic layers were washed with water (2 × 5 mL)
and then saturated aqueous Na2HCO3 (3 × 5 mL).
Subsequently, they were dried and concentrated under reduced
pressure. The product was of suﬃcient purity to be used as an
HPLC standard for subsequent labeling studies (6 mg, 15 μmol,
99%). 1H NMR (600 MHz, chloroform-d) δ 7.45−7.43 (m,
2H), 7.37−7.36 (m, 1H), 7.15 (td, J = 4.5, 2.6 Hz, 1H), 4.84−
4.81 (m, 1H), 4.74 (dd, J = 4.7, 3.5 Hz, 1H), 4.30 (td, J = 3.5, 1.2
Hz, 1H), 4.27−4.24 (m, 1H), 3.73 (p, J = 6.7 Hz, 1H), 3.40
(ddd, J = 10.5, 7.2, 4.7 Hz, 1H), 3.19 (dt, J = 10.5, 7.3 Hz, 1H),
3.15−2.98 (m, 2H), 2.26−2.18 (m, 1H), 2.12−1.98 (m, 2H),
1.84−1.48 (m, 5H), 1.46−1.18 (m, 6H), 0.95 (d, J = 6.2 Hz,
3H). 13C NMR (151 MHz, chloroform-d) δ 158.90, 130.42,
128.89, 128.03, 120.44, 119.64, 113.26, 82.40, 81.26, 77.37,
67.65, 49.09, 43.96, 31.09, 29.85, 24.19, 14.27. Figures S25 and
S26. HPLC [Luna, 5μ, C-18(2) 100 Å column (Phenomenex
Inc. 150 × 4.6 mm2)]; 0.1% TFA in acetonitrile/water (0−
100%) over 15 min; 2 mL/min−rt = 6.7 min.
Radiochemistry. Production of Fluoride-18. [18F]Fluoride
was produced via the (p,n)-reaction in a cyclotron (CTI
Siemens and Scanditronix, Rigshospitalet, Denmark) by
irradiating [18O]H2O with a 11 MeV proton beam.
Radiosynthesis of [18F]ENL30 ([18F]15). The radiosynthesis
of [18F]15 was performed in two steps on a fully automated
system (Scansys Laboratorieteknik synthesis module), begin-
ning with the production of the synthon [18F]ﬂuoroethyl
tosylate ([18F]FETos), which thereafter was used to [18F]ﬂuoro-
alkylate the commercially available precursor SB-269970, as
shown in Scheme 1.
No-carrier-added aqueous 18F-ﬂuoride from the target was
collected at a nonconditioned, activated (10 mL ethanol, 20 mL
water, and dried with air) QMA anion-exchange cartridge (Sep-
Pak Accell Plus QMA Plus Light, chloride form, Waters). A
solution of 20 mg of 1,10-diaza-4,7,13,16,21,24-
hexaoxabicyclo[8.8.8]hexacosane (Kryptoﬁx-222) and 3.3 mg
of K2CO3 in 0.65 mL of 97% aqueous methanol was used to
elute the [18F]ﬂuoride oﬀ the cartridge. The elute was thereafter
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dried by evaporation at ﬁrst 110 °C under nitrogen and then
dried twice again with 1 mL of acetonitrile; during the last step,
the temperature was lowered to 80 °C. To the dried Kryptoﬁx-
222/[18F]ﬂuoride complex, 4 mg (0.011mmol) of the precursor
ethylene di(p-toluenesulfonate), dissolved in 1 mL of MeCN,
was added, and the mixture was further heated for 3 min.
[18F]FETos was isolated using semipreparative HPLC [Luna
5 μmC-18(2) 100 Å column (Phenomenex Inc. 250× 10mm2),
H2O/MeCN (40:60), at a ﬂow rate of 6 mL/min]. The
retention times were 330 s for [18F]FETos and 150 s for ethylene
di(p-toluenesulfonate). The HPLC fraction containing the
[18F]FETos was thereafter diluted with water (60 mL), and
the product was loaded on a Sep-Pak C-18 Plus Short Cartridge,
Waters. The cartridge was dried with nitrogen before the
[18F]FETos was eluted oﬀ with 1 mL of DMSO into a vial
containing 3mg of SB-269970 (0.008mmol) and 5 μL of NaOH
2N, dissolved in 300 μL of DMSO and preheated at 100 °C since
the start of synthesis (40 min). The reaction mixture was further
heated at 100 °C for 25 min before the ﬁnal isolation of [18F]15,
using semipreparative HPLC [Luna 5 μm C-18(2) 100 Å
column (Phenomenex Inc. 250 × 10 mm2), EtOH/0.1%
phosphoric acid in water (25:75), at a ﬂow rate of 3 mL/min].
The ﬁnal product had a retention time of 1200 s and was
collected in a sterile 20 mL vial and diluted with phosphate-
buﬀer (4 mL, 100 mM, and pH 7). The retention times of
[18F]FETos and SB-269970 were 300−400 and 550 s,
respectively.
Determination of Radiochemical Purity and Molar
Activity. The preparation of the ﬁnal product was visually
inspected for clarity and absence of color and particles. Chemical
and radiochemical purities were evaluated by analytical HPLC
[Luna, 5μ, C-18(2) 100 Å column (Phenomenex Inc. 150 × 4.6
mm2); 0.1% TFA in acetonitrile/water (0−100%) over 15 min;
2 mL/min; retention times for [18F]FETos = 7.4 min, [18F]15 =
6.7 min, SB-269970 = 5 min, and [18F]F− = 1−2 min]. TLC
analyses were also carried out to see the ﬁnal content of
[18F]ﬂuoride (SiO2-TLC: eluent: EtOAc, Rf [
18F]15: 0.25 and
Rf [
18F]ﬂuoride ion: 0.0). The total synthesis time was 2.5 h, and
the product could be produced with molar activities between
108 and 197 GBq/μmol (n = 3) and radiochemical purities
above 98%.
Animals. All procedures were conducted in accordance with
the FELASA guidelines for animal research and with approval
from The Danish Animal Experiments Inspectorate (license
number: 2017-15-0201-01283) as well as the Department of
Experimental Medicine, University of Copenhagen. In both the
in vitro and in vivo studies, we used 200−250 g female Long-
EvansWT rats, which were housed in groups of 2−4 animals per
cage in a climate-controlled rodent facility with a 12 h dark/12 h
light cycle. For the PET experiments, the rats were transported
to the scanner at least 1 h before starting the experiment and
they were all fed ad libitum and had free access to water.
In Vitro [18F]15 Autoradiography. After decapitation of
three female Long-Evans WT rats, the brains were quickly
removed, rinsed in ice-cold water, and frozen using dry ice. After
storage at−80 °C, the brains were cut with a cryostat (Microme
HM 500 OM) and 20 μm coronal sections were collected on
glass slides (Thermo Scientiﬁc Superfrost Plus), starting at
bregma −1.8 mm to around −4 mm to get slices containing
thalamus. The brain sections were stored at−80 °C until the day
of the experiment.
In Vitro Autoradiography for KD and Bmax Determi-
nation.On the day of the experiment, the sections were thawed
for 1−2 h prior to the start and thereafter preincubated for 30−
60 min in assay buﬀer (Tris−HCl 50 mM, pH 7.4, rt). The
sections were then incubated for 60 min at room temperate in
assay buﬀer modiﬁed by the addition of [18F]15 to the ﬁnal
concentrations of 0.1, 0.3, 0.7, 1, and 2 nM. For every second
section, SB-269970 (10 μm) was added to both the
preincubation and incubation buﬀer to determine the non-
speciﬁc binding. The incubation was thereafter terminated by
washing two times for 5 min in ice-cold assay buﬀer. The
sections were quickly rinsed in ice-cold water for 20 s and then
rapidly dried under a gentle stream of air before exposure to an
imaging plate (BAS-MS 2040, Fujiﬁlm) overnight.
After obtaining the images using the BAS-1800 plate reader
(Fujiﬁlm), ImageJ v1.52i was used for image analysis and
GraphPad Prism 7 for calculations and statistics. KD and Bmax
were determined in the thalamus, by calculating the speciﬁc
binding (SB) by subtraction of the nonspeciﬁc binding from the
total binding, after drawing a region of interest containing
thalamus on all brain slices (as deﬁned in Figure 1). A calibration
curve of [18F]15 solutions applied on a TLC plate and exposed
together with the slices was used to recalculate the intensity into
concentrations in nanomolar. A one-sited (speciﬁc binding)
nonlinear regression was used to acquire the KD and Bmax values.
In Vitro Autoradiography: Blocking Study. On the day
of the experiment, the sections were thawed for 1−2 h prior to
start and thereafter preincubated for 30−60 min in assay buﬀer
(Tris−HCl 50 mM, pH 7.4, rt). The sections were then
incubated for 60 min at room temperate in assay buﬀer modiﬁed
by the addition of [18F]15 to the ﬁnal concentration of 5 nM.
Either SB-269970 (1, 10, 50, or 100 nM), Haloperidol (1, 10, 50,
or 100 nM, Janssen-Cilag, Birkerød, Denmark), or SA4503 (1,
10, 50, or 100 nM, Merck, Darmstadt, Germany) was added to
both the preincubation and incubation buﬀer to determine
whether a dose-dependent blocking eﬀect could be seen in
thalamus. The incubation was thereafter terminated by washing
two times for 5 min in ice-cold assay buﬀer. The sections were
quickly rinsed in ice-cold water for 20 s and then rapidly dried
under a gentle stream of air before being exposed to an imaging
plate (BAS-MS 2040, Fujiﬁlm) for 60 min. After obtaining the
images using the BAS-1800, ImageJ v1.52i was used for image
analysis andGraphPad Prism 7 for the statistical calculations and
presentation.
PET Evaluation in Rats. Anesthesia was induced at 3−3.5%
isoﬂurane in oxygen and maintained at 2−2.5% during scans.
The PET tracers were given as intravenous (iv) bolus injections
in tail vein catheters at the start of the scan, with the injected
doses being between 15 and 25 MBq. The rats were
subsequently scanned in a high-resolution research tomography
(HRRT) scanner (Siemens AG, Munich, Germany), ﬁrst for a
120 min dynamic PET scan followed by a point source
transmission scan. The scans were performed using a homemade
2 × 2 rat insert, which enabled the possibility of scanning four
rats simultaneously.51 The animals were scanned at baseline and
after receiving iv pretreatment of either elacridar49 (5 mg/kg,
Carbosynth, Compton, U.K.) and/or either SB-269970 (3 mg/
kg), Cimbi-717 (3 mg/kg, synthesized in house),9 haloperidol
(1 mg/kg), or SA4503 (1.5 mg/kg) 15−30 min before tracer
injection. SB-269970, Cimbi-717, and SA4503 were initially
dissolved in DMSO and then added to a 10% β-cyclodextrin
solution (Merck, Darmstadt, Germany). Haloperidol was
diluted to the desired concentration with sterile water.
Reconstruction and Processing of PET Data. The 120
min list-mode PET data was reconstructed using the three-
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dimensional-ordered subset expectation maximization algo-
rithm with attenuation and scatter correction, into 45 dynamic
frames (6× 10, 6× 20, 6× 60, 8× 120, and 19× 300 s), and the
images consisted of 207 planes of 256 × 256 voxels of 1.22 ×
1.22× 1.22 mm3. Using Pmod, an averaged picture of all frames,
except for the ﬁrst 5 min, were reconstructed for each rat and
used for co-registration to a standardized MRI-based rat brain
atlas (Swartz). Volumes of interest (VOIs) containing thalamus
and cerebellum were extracted from the VOI template deﬁned
for the MRI-based atlas.52,53 The outcome measure in the time-
activity curves (TACs) was calculated as radioactive concen-
tration in VOI (kBq/cc) normalized to the injected dose and
corrected for the weight of the animal yielding standardized
uptake values (SUV). GraphPad Prism 7was used for calculating
the AUC for all TACs and displaying the results as a grouped
barplot. For the biodistribution study, VOIs were manually
drawn containing the organs of intrest and visualized as TACs
with the unit ID%/mL.
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